NEW YORK, July 19 - Structural Genomix has appointed Bill Rutter and Stelios Papadopoulos to the company's board of directors, the company said Thursday.
Rutter is a co-founder of Prospect Genomics, a San Francisco-based developer of protein structure prediction software that was acquired in April by Structural Genomix. In addition, Rutter is a founder and chairman emeritus of Chiron, and has served as chairman of the biochemistry and biophysics department at the University of California, San Francisco.
Papadopoulos currently serves as a managing director in investment banking at SG Cowen, specializing in the biotechnology and pharmaceutical sectors. He is a founder and chairman of the board of Exelixis, and a founder and director of Anadys Pharmaceuticals, CellZome, and CellFate.
The addition of Papadopoulos and Rutter brings the number of company directors to eight."With their collective knowledge and experience in drug discovery, investment banking, and management, Stelios and Bill bring tremendous value to our board," George Poste, chairman of Structural Genomix, said in a statement. "Stelios' commitment to strategic business development will facilitate SGX's success, while Bill's background in both academia and commercial life sciences will ensure SGX's dedication to both innovation and sound operations."